Research Article

Aging-Related Endothelial Progenitor Cell Dysfunction and Its Association with IL-17 and IL-23 in HFmrEF Patients

Lijin Zeng,1,2,3 Cong Zhang,2,3 Guoyi Cai,1 Bin Zhang,4,5 Zixia Huang,6 Mingyue Wu,6 Yuanting Zhu,2,3 Liang Luo,7 Hao He,8 and Zhen Yang1,2,3

1Division of Emergency Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3NHC Key Laboratory on Assisted Circulation (Sun Yat-sen University), Guangzhou, China
4Department of Cardiovascular Disease, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, China
5Clinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, China
6Department of Anesthesiology, The Second Affiliated Hospital, Nanhua University, Hengyang, China
7Department of Critical Care Medicine, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
8Department of Cardiology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China

Correspondence should be addressed to Liang Luo; luoliang@mail.sysu.edu.cn, Hao He; hehao2003050@163.com, and Zhen Yang; yangzh8@mail.sysu.edu.cn

Received 17 January 2022; Revised 10 May 2022; Accepted 19 May 2022; Published 26 June 2022

Academic Editor: Alin Cioibica

Copyright © 2022 Lijin Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Aging is an independent risk factor for heart failure (HF), and endothelial progenitor cell (EPC) function decreases with aging. Here, we further investigated whether age has a detrimental effect on circulating EPC function in HF with mildly reduced ejection fraction (HFmrEF) and its relationship with systemic inflammation.

Methods. 58 HFmrEF patients were recruited. The adhesive, migrative, and proliferative activities of circulating EPCs, MAGGIC scores, and plasma interleukin (IL)-17 and IL-23 levels of these patients were assessed.

Results. Older patients with HFmrEF had higher MAGGIC scores and lower circulating EPC adhesion, migration, and proliferation than younger patients. The similar tendency was observed in plasma IL-17 and IL-23 levels. The EPC functions were negatively associated with MAGGIC scores and plasma IL-17 or IL-23 levels.

Conclusions. In patients with HFmrEF, aging leads to attenuated circulating EPC function, which is correlated with disease severity and systemic inflammation. The present investigation provides some novel insights into the mechanism and intervention targets of HFmrEF.

1. Introduction

Heart failure (HF) is the leading cause of cardiovascular mortality and places great stress on public health systems globally [1, 2]. Its incidence and mortality increase significantly with age [3]. The 2021 HF guidelines define HF with mildly reduced ejection fraction (HFmrEF) as having an ejection fraction of 41–49% [4], while it was defined as the EF of 40–49% in the 2016 European Society of Cardiology (ESC) Guidelines [5]. HFmrEF accounts for 10–24.2% of HF patients [6–8] and has an all-cause mortality 2–3 times higher in the elderly [9]. The Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) score includes 13 independent predictors of mortality and predicts the 1- and 3-year all-cause mortality of HF [10, 11]. Although many studies have examined the characteristics of HFmrEF since it was first named in the 2016 ESC guidelines [5], the effect of aging on MAGGIC score in HFmrEF patients is still unknown.

Endothelial progenitor cells (EPCs) derived from bone marrow help repair injured endothelium by differentiating into endothelial cells [12]. The EPC level is reduced in advanced HF [13] and is an independent predictor of mortality in HF [14, 15]. A recent study reported that the number and migratory capacity of EPCs did not decrease with
Table 1: Clinical and biochemical characteristics of younger and older patients with HFmrEF.

| Characteristics            | Younger group (n = 25)                           | Older group (n = 33)                          |
|----------------------------|--------------------------------------------------|------------------------------------------------|
| Age (years)                | 58.0 (47.0, 60.5)                                 | 80.0 (70.5, 84.0)†                             |
| Male (n, %)                | 23 (92.0%)                                       | 25 (75.8%)                                     |
| Heart rate (time/min)      | 80.0 (76.0, 102.0)                                | 80.0 (73.5, 93.0)                              |
| Systolic BP (mmHg)         | 128.2 ± 21.0                                     | 127.7 ± 20.7                                   |
| Diastolic BP (mmHg)        | 78.5 ± 12.2                                      | 72.0 ± 14.0                                    |
| BMI (kg/m²)                | 20.6 (20.3, 23.9)                                | 20.0 (18.7, 23.7)                              |
| Plasma glucose (mmol/L)    | 7.1 (5.8, 8.7)                                   | 7.9 (6.1, 9.5)                                 |
| Cr (mmol/L)                | 109.0 (78.5, 225.0)                              | 108.0 (75.5, 184.5)                            |
| TC (mmol/L)                | 4.3 ± 1.9                                        | 3.9 ± 1.3                                      |
| TG (mmol/L)                | 1.2 (1.0, 2.0)                                   | 1.2 (0.8, 1.6)                                 |
| HDL (mmol/L)               | 0.9 (0.7, 1.1)                                   | 1.0 (0.8, 1.4)                                 |
| LDL (mmol/L)               | 2.9 ± 1.2                                        | 2.4 ± 0.9                                      |
| NT pro-BNP (pg/mL)         | 1883.0 (435.3, 30168.5)                          | 4288.0 (817.0, 23584.0)                        |
| Septal E’ (cm/s)           | 5.0 (4.0, 6.5)                                   | 5.0 (3.5, 6.0)                                 |
| LVEDD (mm)                 | 56.4 ± 5.2                                       | 54.6 ± 7.6                                     |
| TAPSE (mm)                 | 19.3 ± 4.6                                       | 19.6 ± 3.9                                     |
| LVEF (%)                   | 44.0 (42.0, 46.5)                                | 43.0 (42.0, 45.0)                              |
| MAGGIC score               | 11.0 (8.5,20.0)                                  | 29.0 (23.5,32.5)†                              |

Abbreviations: BMI: Body mass index; BP: Blood pressure; Cr: Serum creatinine; TC: Total cholesterol; TG: Triglyceride; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; LVEDD: Left ventricular end-diastolic diameter; TAPSE: Tricuspid annulus systolic plane excursion; LVEF: Left ventricular ejection fraction; MAGGIC: Meta-analysis Global Group in Chronic Heart Failure. Notes: Normally distributed data are given as the mean ± SD and nonnormally distributed data as the median (25%, 75%). The differences between the groups with nonnormally distributed data were compared with the Mann–Whitney U-test, while the Student’s t-test was used for normally distributed data. †P < 0.05 vs. younger group.

Figure 1: EPC function of younger and older patients. The adhesion (a), migration (b), and proliferation (c) of circulating EPCs decreased in older HFmrEF patients. Data were given as mean ± SD and compared with the Student’s t-test. †P < 0.05 vs. younger group.
Age in patients with HF with a reduced ejection fraction (HFrEF) [16]. However, the influence of aging on circulating EPCs in HFmrEF is unclear.

Aging is closely associated with inflammation, which is mainly induced by damage-associated molecular patterns (DAMPs) via interactions with cell receptors and the upregulation of proinflammatory cytokines [17, 18]. The severity of HF is positively correlated with proinflammatory cytokine levels [19, 20], which are also independent predictors of cardiovascular events in older patients [21]. IL-17 is an important proinflammatory cytokine that increases with age and is related to the New York Heart Association (NYHA) class of HF [22, 23]. IL-17 is maintained mainly by IL-23, another cytokine that induces Th17 differentiation [24]. Previously, we found that IL-17 was negatively related to EPC function in older non-ST segment elevation myocardial infarction patients [25]. We hypothesized that increasing IL-17 and IL-23 might be the mechanism underlying the alteration in function of circulating EPCs in aging patients with HFmrEF. Therefore, we assessed the variation in MAGGIC score function of circulating EPCs, and plasma IL-17 and IL-23 levels. Table 1 lists the basic clinic characteristics.

2. Methods

2.1. Study Population. Patients diagnosed with HFmrEF were divided into older (≥65 years) and younger (<65 years) groups. The HFmrEF inclusion criterion was a clinician-judged HF with a left ventricular ejection fraction (LVEF) of 41–49% [4]. All patients were older than 18 years and provided venous blood to assess the quality of circulating EPCs and plasma IL-17 and IL-23 levels. Table 1 lists the basic clinic characteristics.

2.2. MAGGIC Score Calculation. MAGGIC scores which included age, gender, EF, body mass index, systolic blood pressure, time since HF diagnosis, NYHA class, serum creatinine, chronic obstructive pulmonary disease, diabetes, current smoking, and current therapy with beta-blocker, angiotensin-receptor blockers, and ACE-inhibitor were calculated as reported previously [11].

2.3. EPC Function. The adhesion, migration, and proliferation of circulating EPCs were assessed as reported previously [26–29]. Briefly, EPC adhesion was determined by fibronectin-coated culture plates as reported previously [26]. EPC migration was evaluated by modified Boyden chamber containing EBM-2 and supplemented with vascular endothelial growth factor (VEGF) as reported previously [27, 28]. EPC proliferation was analysed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, (MTT) assay [27–29].
ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA) and Human IL-23 ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA) to measure the plasma IL-17 and IL-23 levels according to the manufacturer’s instructions.

2.5. Statistical Analysis. SPSS ver. 23.0 (SPSS, Chicago, IL, USA) was used to analyse the statistics. The differences between the groups with nonnormally distributed data were compared with the Mann–Whitney U-test, while the Student’s t-test was used for normally distributed data. Correlations of normally distributed data were analysed with Pearson’s test, and nonnormally distributed data were analysed with Spearman’s test. Statistical significance was defined as \( P < 0.05 \).

3. Results

3.1. Baseline Characteristic. The study enrolled 25 younger (<65 years) and 33 older (≥65 years) HFmrEF patients. Table 1 lists the baseline characteristics and laboratory results of all patients. Characteristics including sex, heart rate, blood pressure, BMI, and laboratory findings including creatinine, plasma glucose, HDL, LDL, triglycerides, cholesterol, NT pro-BNP, septal E’, left ventricular end-diastolic diameter, tricuspid annulus systolic plane excursion, and LVEF were comparable between the younger and the older HFmrEF group (all \( P > 0.05 \)). MAGGIC score was higher in older group than that in younger group (\( P < 0.05 \)).

3.2. Differences in EPC Function between Younger and Older HFmrEF Patients. As the adhesion of circulating EPCs was evaluated by fibronectin-coated culture plates, the EPC adhesion was reduced in older HFmrEF patients when compared with younger HFmrEF patients (Figure 1(a), \( P < 0.05 \)). As the migration of circulating EPCs was tested by modified Boyden chamber, the EPC migration also decreased in older HFmrEF patients in comparison with younger HFmrEF patients (Figure 1(b), \( P < 0.05 \)). Similarly, as the proliferation of circulating EPCs was detected by MTT assay, the EPC proliferation was lessened in older HFmrEF patients (Figure 1(c), \( P < 0.05 \)).

3.3. EPC Function Impaired More in the High MAGGIC Score Group. The patients were divided into two groups according to whether the MAGGIC score was ≥25 or not, and the circulating EPC function was compared between the two groups. As Figure 2 shows, the adhesive function of circulating EPCs in the high-score group was significantly lower than that in the low-score group (\( P < 0.05 \)). Meanwhile, the migration and proliferation of circulating EPCs in the high-score group were inferior to those in the low-score group (all \( P < 0.05 \)).
3.4. Relationship between MAGGIC Score and EPC Function.

As Figure 3 exhibits, the circulating EPC adhesion negatively correlated with the MAGGIC score in the HFmrEF patients \( (P < 0.05) \). The migration and proliferation of circulating EPCs were also negatively connected with MAGGIC score in the HFmrEF patients \( (P < 0.05) \).

3.5. Plasma IL-17 and IL-23 Levels in Younger and Older Patients and the MAGGIC Score.

The plasma IL-17 level was higher in older HFmrEF patients than that in the younger HFmrEF patients \( (P < 0.05) \). Likewise, the plasma IL-23 in the older HFmrEF patients exceeded more than that in the younger HFmrEF patients \( (P < 0.05) \). Moreover, the plasma IL-17 and IL-23 levels were also elevated in the high MAGGIC score group when compared with the low MAGGIC score group \( (P < 0.05) \).

3.6. The Correlation between Inflammatory Cytokines and EPC Function or MAGGIC Score.

The MAGGIC score was positively related to plasma IL-17 or IL-23 level in the HFmrEF patients \( (P < 0.05) \). Conversely, the adhesion of circulating EPCs negatively correlated with plasma IL-17 or IL-23 level in the HFmrEF patients \( (P < 0.05) \). The circulating EPC migrative function was also negatively associated with plasma IL-17 or IL-23 level in the HFmrEF patients \( (P < 0.05) \). In line with migration and adhesion, plasma IL-17 or IL-23 level had a negative relationship with the circulating EPC proliferation \( (P < 0.05) \).

3.7. The Correlation Between Age and EPC Function, MAGGIC Score, or Inflammatory Cytokines.

Positive relationships were observed between age and MAGGIC score in the HFmrEF patients \( (P < 0.05) \), indicating the effect of aging on disease severity in HFmrEF. Negative correlations between age and EPC adhesive, migrative, and proliferative function were also discovered in the HFmrEF patients \( (P < 0.05) \). Besides that, age was inversely related to plasma IL-17 or IL-23 levels in the HFmrEF patients \( (P < 0.05) \).

4. Discussion

This study revealed an age-related increase in disease severity and reduced circulating EPC function in HFmrEF patients. Similarly, plasma IL-17 and IL-23 levels increased more in older HFmrEF patients than in younger patients and were closely related to disease severity and circulating EPC function. This is the first report of age differences in MAGGIC scores and circulating EPC function in HFmrEF, which is at least partly correlated with the increment in pro-inflammatory cytokines.

Although aging is an independent predictor of HF prognosis [3], no previous studies have examined how aging affects the severity of HFmrEF. Here, we found that the MAGGIC score, an effective prognostic assessment method...
for HF, was higher in older HFmrEF patients than in younger ones, implying that aging contributes to the poor prognosis of HFmrEF. It is essential to determine the underlying mechanism.

Previous studies have reported that aging impairs EPC function, which is critical for endothelial repair [30, 31], and that sustained reduction of EPC level contributes to HF via its effect on structural abnormalities [32]. Most research has focused on the relationship between the numbers of EPCs and HF, whereas only a few studies have provided data on HF-related EPC function, and the limited data suggested that EPC activity is impaired in HF [33, 34]. Interestingly, we found that aging aggravated circulating EPC dysfunction in HFmrEF patients, which differed from the findings of Sandri et al., who reported that while EPC function tended downward with age, the difference was not significant [16]. This discrepancy may be mainly due to differences between study populations: Sandri et al. assessed HFrEF patients, and we assessed HFmrEF patients. Our investigation further found that EPC adhesion and proliferation were also mitigated in HFmrEF patients, implying the panorama of age-related qualitative alteration of endothelial repair potential in HFmrEF. In addition, we also found that EPC function was negatively related to the MAGGIC score,

Figure 5: Relationships between proinflammatory cytokines and MAGGIC score or EPC function. MAGGIC score was positively correlated with IL-17 (a) and IL-23 (E). EPC adhesion, migration, and proliferation were negatively related to IL-17 (b)–(d) and IL-23 (f)–(h). Correlations of normally distributed data were analysed with Pearson’s test, and nonnormally distributed data were analysed with Spearman’s test.
indicating that aging worsened the prognosis of HFmrEF partly through impaired EPC function, while increased EPC activity may contribute to improvement in the prognosis of aging HFmrEF patients.

Proinflammatory cytokines increase with age [22, 25, 35], and IL-17 level is associated with the severity and prognosis of HF [23]. Previous studies have implicated the IL-23/IL-17 axis in the development of myocarditis and cardiac remodelling after myocardial infarction [36–38]. Here, we compared plasma IL-17 and IL-23 levels in HFmrEF patients and found that the older HFmrEF group had higher levels than the younger group. Additionally, IL-17 and IL-23 were positively associated with the MAGGIC score, consistent with the results of a previous study reporting a strong correlation between HF and proinflammatory cytokines [23]. Proinflammatory mediators can impair EPC activity partly by regulating NF-κB [39, 40]. Previously, we showed that IL-6 and IL-17 were negatively related to EPC function in non-ST segment elevation myocardial infarction patients [25]. In line with previous reports, our study demonstrated that IL-17 and IL-23 levels were inversely related to EPC function in HFmrEF patients, indicating that the aging-related increment of IL-17 and IL-23 might partly be the mechanism underlying circulating EPC dysfunction in

**Figure 6:** Relationships between age and the MAGGIC score, inflammatory cytokines, or EPC function. Positive relationships were observed between age and the MAGGIC score (a), IL-17 (b), and IL-23 (c), but negative correlations were found between age and EPC adhesion (d), migration (e), and proliferation (f). Correlations of normally distributed data were analysed with Pearson’s test, and nonnormally distributed data were analysed with Spearman’s test.
HFmrEF. IL-17/IL-23 axis may be a potential intervention target for the treatment of older patients with HFmrEF.

There are clinical implications in the present study. First, our data indicated that EPC function was more seriously impaired in older HFmrEF patients and was related to disease severity, implying that EPC function may act as a surrogate biomarker for assessing the prognosis of HFmrEF. Recovering EPC function may be a latent therapeutic strategy for older HFmrEF patients. Second, the weakened EPC function may be partly due to the excessive activation of IL-17/IL-23 axis in HFmrEF. Thus, anti-inflammation intervention may be beneficial for the treatment of HFmrEF patients.

Our study had some limitations. First, we did not uncover the exact mechanism underlying the effect of IL-17 or IL-23 on EPC function. Further research is needed to address it. Second, the investigation did not pursue the MACE (Major Adverse Cardiovascular Events) in older HFmrEF patients. Previous research has verified the role of MAGGIC score in predicting the mortality of HF [10, 11]. As the relationship between MAGGIC score and EPC function is revealed by our study, it can be inferred that EPC function may be valuable in predicting the prognosis of HFmrEF.

5. Conclusions

This study demonstrated that the activity of circulating EPCs was impaired in older HFmrEF patients, which was related to disease severity. The impaired EPC function in elderly patients with HFmrEF might be partly attributable to systemic inflammation. Our findings suggest that improvement in attenuated endothelial repair ability may be helpful for the treatment of aging HFmrEF.

Data Availability

The original data can be obtained from the corresponding author if it is permitted by all authors.

Ethical Approval

This study was approved by the Ethical Committee of First Affiliated Hospital of Sun Yat-sen University.

Conflicts of Interest

The authors declare no competing interests.

Authors’ Contributions

Lijin Zeng, Cong Zhang, and Guoyi Cai contributed equally to this work and share first authorship.

Acknowledgments

The study was supported by the grants from the National Natural Science Foundation of China (82171578), the International Scientific and Technological Cooperation Project of Guangzhou Economic and Technological Development Zone (2017GH13), and the Characteristic Innovation Research Project of College Teachers (2020SWYY04).

References

[1] A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics–2014 update: a report from the American Heart Association,” Circulation, vol. 129, no. 3, pp. e28–e292, 2014.
[2] A. P. Ambrosy, G. C. Fonarow, J. Butler et al., “The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries,” Journal of the American College of Cardiology, vol. 63, no. 12, pp. 1123–1133, 2014.
[3] G. C. Fonarow, W. T. Abraham, N. M. Albert et al., “Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF),” The American Journal of Cardiology, vol. 104, no. 1, pp. 107–115, 2009.
[4] B. Bozkurt, A. J. S. Coats, H. Tsutsui et al., “Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association,” European Journal of Heart Failure, vol. 23, no. 3, pp. 352–380, 2021.
[5] P. Ponikowski, A. A. Voors, S. D. Anker et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,” European Heart Journal, vol. 37, no. 27, pp. 2129–2200, 2016.
[6] A. S. Koh, W. T. Tay, T. H. K. Teng et al., “A comprehensive population-based characterization of heart failure with mid-range ejection fraction,” European Journal of Heart Failure, vol. 19, no. 12, pp. 1624–1634, 2017.
[7] V. Bhambhani, J. R. Kizer, J. A. C. Lima et al., “Predictors and outcomes of heart failure with mid-range ejection fraction,” European Journal of Heart Failure, vol. 20, no. 4, pp. 651–659, 2018.
[8] O. Chioncel, M. Lainscak, P. M. Seferovic et al., “Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry,” European Journal of Heart Failure, vol. 19, no. 12, pp. 1574–1585, 2017.
[9] X. Chen, G. Savarese, U. Dahlström, L. H. Lund, and M. Fu, “Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction,” Clinical Research in Cardiology, vol. 108, no. 12, pp. 1394–1405, 2019.
[10] P. Codina, J. Lupon, A. Borrellas et al., “Head-to-head comparison of contemporary heart failure risk scores,” European Journal of Heart Failure, vol. 23, no. 12, pp. 2035–2044, 2021.
[11] S. J. Pocock, C. A. Ariti, J. J. V. McMurray et al., “Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies,” European Heart Journal, vol. 34, no. 19, pp. 1404–1413, 2013.
[12] C. Kalka, H. Masuda, T. Takahashi et al., “Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic
neovascularization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3422–3427, 2000.

13. M. Valgimigli, G. M. Rigolin, A. Fucili et al., “CD34” and endothelial progenitor cells in patients with various degrees of congestive heart failure,” Circulation, vol. 110, no. 10, pp. 1209–1212, 2004.

14. Y. Michowitz, E. Goldstein, D. Wexler, D. Sheps, G. Keren, and J. George, “Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure,” Heart, vol. 93, no. 9, pp. 1046–1050, 2007.

15. L. Koller, P. Hohensinner, P. Sulzgruber et al., “Prognostic relevance of circulating endothelial progenitor cells in patients with chronic heart failure,” Thrombosis and Haemostasis, vol. 116, no. 8, pp. 309–316, 2016.

16. M. Sandri, M. Viehmann, V. Adams et al., “Chronic heart failure and aging – effects of exercise training on endothelial function and mechanisms of endothelial regeneration: results from the Leipzig Exercise Intervention in Chronic heart failure and Aging (LEICA) study,” European Journal of Preventive Cardiology, vol. 23, no. 4, pp. 349–358, 2016.

17. H. Volt, J. A. Garcia, C. Doerrir et al., “Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin,” Journal of Pineal Research, vol. 60, no. 2, pp. 193–205, 2016.

18. M. Pinti, E. Cevenini, M. Nasi et al., “Circulating mitochondrial DNA increases with age and is a familiar trait: implications for ‘inflamm-aging’,” European Journal of Immunology, vol. 44, no. 5, pp. 1552–1562, 2014.

19. G. Torre-Amione, S. Kapadia, C. Benedict, H. Oral, J. B. Young, and D. L. Mann, “Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD),” Journal of the American College of Cardiology, vol. 27, no. 5, pp. 1201–1206, 1996.

20. A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, and D. L. Mann, “Cytokines and cytokine receptors in advanced heart failure,” Circulation, vol. 103, no. 16, pp. 2055–2059, 2001.

21. M. Cesari, B. W. Penninx, A. B. Newman et al., “Inflammatory markers and onset of cardiovascular events,” Circulation, vol. 108, no. 19, pp. 2317–2322, 2003.

22. H. W. Stout-Delgado, W. Du, A. C. Shirali, C. J. Booth, and D. R. Goldstein, “Aging promotes neutrophil-induced mortality by augmenting IL-17 production during viral infection,” Cell Host & Microbe, vol. 6, no. 5, pp. 446–456, 2009.

23. X. F. Li, D. Pan, W. L. Zhang, J. Zhou, and J. J. Liang, “Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients,” Genes, Genomics and Molecular Research, vol. 15, no. 2, 2016.

24. S. Aggarwal, N. Ghildari, M. H. Xie, F. J. de Sauvage, and A. L. Gurney, “Interleukin-23 promotes a distinct CD4+ T cell activation state characterized by the production of interleukin-17,” The Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910–1914, 2003.

25. L. Zeng, C. Zhang, Y. Zhu et al., “Hypofunction of circulating endothelial progenitor cells and aggravated severity in elderly male patients with non-ST segment elevation myocardial infarction: its association with systemic inflammation,” Frontiers in Cardiovascular Medicine, vol. 8, article 687590, 2021.

26. P. H. Huang, Y. H. Chen, Y. L. Chen, T. C. Wu, J. W. Chen, and S. J. Lin, “Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome X,” Heart, vol. 93, no. 9, pp. 1064–1070, 2007.

27. S. H. Wu, F. Zhang, S. Yao et al., “Shear stress triggers angio genesis of late endothelial progenitor cells via the PTEN/Akt/GTPCH/BH4 pathway,” Stem Cells International, vol. 2020, Article ID 5939530, 13 pages, 2020.

28. Y. P. Bai, S. Xiao, Y. B. Tang et al., “Shear stress-mediated upregulation of GTP cyclohydrolase/tetrahydrobiopterin pathway ameliorates hypertension-related decline in reendothelialization capacity of endothelial progenitor cells,” Journal of Hypertension, vol. 35, no. 4, pp. 784–797, 2017.

29. Z. Yang, L. Chen, C. Su et al., “Impaired endothelial progenitor cell activity associated with reduced arterial elasticity in patients with essential hypertension,” Clinical and Experimental Hypertension, vol. 32, no. 7, pp. 444–452, 2010.

30. E. Kushner, G. Van Guilder, O. MacEneaney et al., “Aging and endothelial progenitor cell release of proangiogenic cytokines,” Age and Ageing, vol. 39, no. 2, pp. 268–272, 2010.

31. C. Heiss, S. Keymel, U. Niesler, J. Ziemann, M. Kelm, and C. Kalka, “Impaired progenitor cell activity in age-related endothelial dysfunction,” Journal of the American College of Cardiology, vol. 45, no. 9, pp. 1441–1448, 2005.

32. C. H. Chiang, P. H. Huang, H. B. Leu et al., “Decreased circulating endothelial progenitor cell levels in patients with heart failure with preserved ejection fraction,” Cardiology, vol. 126, no. 3, pp. 191–201, 2013.

33. C. K. Kissel, R. Lehmann, B. Assmus et al., “Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure,” Journal of the American College of Cardiology, vol. 49, no. 24, pp. 2341–2349, 2007.

34. W. P. Huang, W. H. Yin, J. S. Chen, P. H. Huang, J. W. Chen, and S. J. Lin, “Fenofibrate reverses dysfunction of EPCs caused by chronic heart failure,” Journal of Cardiovascular Translational Research, vol. 13, no. 2, pp. 158–170, 2020.

35. R. Vafiathan, M. Ashman, and D. Asthana, “Effects of ageing on the immune system: infants to elderly,” Scandinavian Journal of Immunology, vol. 83, no. 4, pp. 255–266, 2016.

36. I. Sonderegger, T. A. Rohn, M. O. Kurrer et al., “Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis,” European Journal of Immunology, vol. 36, no. 11, pp. 2849–2856, 2006.

37. J. M. Myers, L. T. Cooper, D. C. Kem et al., “Cardiac myosin-Th17 responses promote heart failure in human myocarditis,” JCI Insight, vol. 1, no. 9, 2016.

38. X. Yan, T. Shichita, Y. Kitazuma et al., “Deleterious effect of the IL-23/IL-17A axis and γδ T cells on left ventricular remodeling after myocardial infarction,” Journal of the American Heart Association, vol. 1, no. 5, article e004408, 2012.

39. L. Sun, S. Chen, H. Gao, L. Ren, and G. Song, “Visfatin induces the apoptosis of endothelial progenitor cells via the induction of pro-inflammatory mediators through the NF-κB pathway,” International Journal of Molecular Medicine, vol. 40, no. 3, pp. 637–646, 2017.

40. Y. Sun, S. Chen, G. Song et al., “Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action,” International Journal of Molecular Medicine, vol. 30, no. 3, pp. 622–628, 2012.